Management of patients with biochemical recurrence after local therapy for prostate cancer

Research output: Contribution to journalReview article


Nearly three-quarters of a million American men who have been treated with prostatectomy and/or radiation therapy experience an increasing prostate-specific antigen level known as biochemical recurrence. Although androgen-deprivation therapy remains a reasonable option for some men with biochemical recurrence, deferring androgen ablation or offering nonhormonal therapies may be appropriate in patients in whom the risk of clinical or metastatic progression and prostate cancer-specific death is low. A risk-stratified approach informed by the patient's prostate-specific antigen kinetics, comorbidities, and personal preferences is recommended to determine the best management approach.

Original languageEnglish (US)
Pages (from-to)1205-1219
Number of pages15
JournalHematology/Oncology Clinics of North America
Issue number6
StatePublished - Dec 1 2013



  • Androgen-deprivation therapy
  • Biochemical recurrence
  • Hormonal therapy
  • Prostate cancer
  • Rising prostate-specific antigen

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this